Advertisement
The depositary for the offer has advised Hologic and the Purchaser that,as of the expiration of the initial offering period, a total of approximately45,225,950 Third Wave shares were validly tendered to the Purchaser (includingshares tendered via the guaranteed delivery procedure) and not withdrawn,representing approximately 92.1% of the outstanding common stock of ThirdWave. The Purchaser has accepted for payment all Third Wave shares that werevalidly tendered during the initial offering period.
Advertisement
Hologic also announced that the Purchaser has commenced a subsequentoffering period for all remaining shares of Third Wave common stock to permitstockholders who have not yet tendered their shares the opportunity to do so.This subsequent offering period will expire at 12:00 midnight, New York Citytime, on Wednesday, July 23, 2008, unless further extended. Any such extensionwill be followed by a public announcement no later than 9:00 a.m., New YorkCity time, on the next business day after the subsequent offering period wasscheduled to expire.
The same $11.25 per share price offered in the prior offering period willbe paid during the subsequent offering period. All shares validly tenderedduring this subsequent offering period will be immediately accepted andpayment will be made promptly after acceptance, in accordance with the termsof the offer. Procedures for tendering shares during the subsequent offeringperiod are the same as during the initial offering period with two exceptions:(1) shares cannot be delivered by the guaranteed delivery procedure, and (2)pursuant to Rule 14d-7(a)(2) promulgated under the Securities Exchange Act of1934, as amended, shares tendered during the subsequent offering period maynot be withdrawn.
Pursuant to the terms of the previously announced merger agreement,Hologic expects to effect a merger of the Purchaser with and into Third Wave.In the merger, the Purchaser will acquire all other Third Wave shares (otherthan those as to which holders properly exercise appraisal rights) at the same$11.25 per share price, without interest and less any required withholdingtaxes, that was paid in the tender offer. As a result of the merger, ThirdWave will become a wholly-owned subsidiary of Hologic. Hologic intends tocomplete the merger as soon as practicable. If, as a result of additionalshares tendered and purchased in the subsequent offering period or otherwise,the Purchaser becomes the owner of at least 90% of the outstanding Third Waveshares, the Purchaser will be able to effect the merger without the need for ameeting of Third Wave stockholders. Third Wave stockholders who continue tohold their shares at the time of the merger and fulfill certain otherrequirements of Delaware law will have appraisal rights in connection with themerger.
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premiumdiagnostics, medical imaging systems and surgical products dedicated toserving the healthcare needs of women. Hologic's core business units arefocused on breast health, diagnostics, GYN surgical, and skeletal health.Hologic provides a comprehensive suite of technologies with products formammography and breast biopsy, radiation treatment for early-stage breastcancer, cervical cancer screening, treatment for menorrhagia, osteoporosisassessment, preterm birth risk assessment, and mini C-arm for extremityimaging. For more informat
